Amneal Q2 net revenue $796M (+10% YoY); GAAP EPS $0.18; raises FY 2026 guidance

Amneal Pharmaceuticals, Inc.

Net revenue $796M (+10% YoY); GAAP net income $58M, diluted EPS $0.18 (vs $0.07 YoY).
Adjusted EBITDA $206M (+12% YoY); adjusted diluted EPS $0.30 (+20% YoY).
Specialty revenue +17% driven by CREXONT, BREKIYA, UNITHROID; Affordable Medicines +13% on complex portfolio.
Raising full-year 2026 guidance for second time this year; debt repricing in July reduces interest cost.
Pending Kashiv transaction to establish biosimilars as new growth vertical.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.